LOGIN
Teriparatide increases BMD in patients with glucocorticoid-Induced osteoporosis
August 2013
Teriparatide increases BMD in patients with glucocorticoid-Induced osteoporosis
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
N Engl J Med. 2007 Nov 15;357(20):2028-39Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
428 patients with glucocorticoid-induced osteoporosis were randomised to receive one of two treatments. The first group received a treatment of 20 μg teriparatide daily while the second group received a 10 mg alendronate treatment. The primary outcome was change in bone mineral density at the lumbar spine from baseline to the 18-month follow-up. Results indicated that bone mineral density increas...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.